Autologous tumor-infiltrating lymphocytes (HS-IT101) with low-dose lymphodepletion and IL-2 infusion for the treatment of advanced solid tumors: A phase I clinical trial. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results